Articles

Find an Article

Filter articles

Applied Filters

Showing 231 to 240 of 319 results

Stemming the tide of rejections

Mexico16-06-2015Jasmin Maqueda

Mexican patent examiners usually reject patents directed to human embryonic stem cells, but applications filed after 2008 may have a greater chance of being approved, as Jasmin Maqueda of Becerril, Coca & Becerril describes.

TRIPS and compulsory licences: raising the bar

US16-06-2015Sandra Kuzmich and Russell Garman

The proposed Trans-Pacific Partnership seemingly contains a bid by the US to increase standards for compulsory licences above those already in place internationally, say Sandra Kuzmich and Russell Garman of Frommer Lawrence & Haug.

Ogres and trolls

US16-06-2015Steve Coyle, Leslie-Anne Maxwell, Chad Dever

The inter partes review system was set up as a cheaper way of invalidating patents than litigation. Given the high success rate, and the large number of ‘patent trolls’ involved, is it likely that troll activity will be dampened? Steve Coyle, Leslie-Anne Maxwell and Chad Dever of Cantor Colburn investigate.

Method patents: Questions of diagnosis

US16-06-2015MaryAnne Armstrong

The Supreme Court’s Limelight decision makes it particularly difficult for the owners of diagnostic method patents to enforce those patents against a third party selling the assay. MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch describes the current situation.

SPCs: The semantics of protection

International16-06-2015Michael Pears

Despite the SPC Regulation having been in existence for decades, applicants are still left to navigate uncertain waters on issues of fundamental importance when it comes to ‘combination’ therapies, as Michael Pears of Potter Clarkson reports.

Digital health: Issues of patentability

US16-06-2015Marsha Gillentine and Michelle Holoubek

Recent changes in US patent law have made protecting and enforcing patents directed to digital healthcare inventions more challenging, as Marsha Gillentine and Michelle Holoubek of Sterne, Kessler, Goldstein & Fox explain.

TPP: Coming into line

International16-06-2015

As far we know, the IP chapter in the proposed Trans-Pacific Partnership agreement contains provisions on modernising plant breeders’ rights, but not all the participating countries are currently on the same page, as LSIPR reports.

Preview: 2015 BIO International Convention

US11-06-2015

LSIPR picks five sessions IP professionals won’t want to miss at this year’s BIO International Convention in Philadelphia, from June 15 to 18.

Gilead: Treating the seven million

International11-06-2015

Pharma company Gilead has been in the headlines since it launched its blockbuster drug Sovaldi with a hefty price tag. Less reported, however, are its numerous patent licensing deals that ensure wider access to medicines in the developing world. LSIPR spoke to Christina Carlson, senior counsel at Gilead Sciences, to find out more.

New players on the patent chess board

US14-05-2015Marc Cavan and Phillip Kurs

The ability of third parties to participate in patent challenges has led to new dynamics, including the possibility of parties profiting from movements in stock price and the prospect of patent oppositions by not-for-profit proxies, as Marc Cavan and Phillip Kurs of law firm Ropes & Gray describe.

Showing 231 to 240 of 319 results

LSIPR